Apixaban

ApprovedTerminated

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Deep Vein Thrombosis

Conditions

Deep Vein Thrombosis

Trial Timeline

Feb 19, 2019 → Jun 3, 2019

NCT ID

NCT03590743

About Apixaban

Apixaban is a approved stage product being developed by Pfizer for Deep Vein Thrombosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03590743. Target conditions include Deep Vein Thrombosis.

What happened to similar drugs?

3 of 11 similar drugs in Deep Vein Thrombosis were approved

Approved (3) Terminated (1) Active (8)

✅Dalteparin sodium injection + WarfarinPfizerApproved

✅Low Molecular Weight Heparin (dalteparin)PfizerApproved

✅ClexaneSanofiApproved

🔄Apixaban + Unfractionated Heparin (UFH) + WarfarinPfizerPhase 3

🔄Enoxaparin + Placebo + Apixaban + PlaceboBristol Myers SquibbPhase 3

🔄Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placeboBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04681482	Pre-clinical	Completed	Nov 2, 2020	Nov 3, 2020	Atrial Fibrillation
NCT03590743	Approved	Terminated	Feb 19, 2019	Jun 3, 2019	Deep Vein Thrombosis
NCT02369653	Phase 3	Completed	Oct 22, 2015	Jul 7, 2021	Lymphoma
NCT01884337	Approved	Completed	Mar 24, 2015	Jun 4, 2018	Anticoagulation
NCT01707394	Phase 1	Completed	Jan 10, 2013	Jun 30, 2020	Thromboembolism
NCT02034591	Phase 1	Completed	Oct 1, 2011	Nov 1, 2011	Healthy Subjects
NCT01195727	Phase 1	Terminated	Jul 26, 2011	Jul 16, 2012	Venous Thromboembolism
NCT02034578	Phase 1	Completed	Jul 1, 2011	Aug 1, 2011	Healthy Volunteers
NCT02034565	Phase 1	Completed	Feb 1, 2010	Mar 1, 2010	Healthy Volunteers

Competing Products

20 competing products in Deep Vein Thrombosis

See all competitors

Product	Company	Stage	Hype Score
Edoxaban low dose + Edoxaban high dose	Daiichi Sankyo	Phase 1	29
edoxaban tosylate + enoxaparin/unfractionated heparin + warfarin	Daiichi Sankyo	Phase 2	35
Fragmin (dalteparin sodium )	Pfizer	Pre-clinical	26
Fluconazole	Pfizer	Pre-clinical	26
Dalteparin sodium injection + Warfarin	Pfizer	Approved	43
Low Molecular Weight Heparin (dalteparin)	Pfizer	Approved	43
Apixaban + Unfractionated Heparin (UFH) + Warfarin	Pfizer	Phase 3	40
Apixaban	Bristol Myers Squibb	Phase 2	35
Enoxaparin + Placebo + Apixaban + Placebo	Bristol Myers Squibb	Phase 3	40
Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placebo	Bristol Myers Squibb	Phase 3	40
Apixaban	Bristol Myers Squibb	Pre-clinical	26
Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placebo	Bristol Myers Squibb	Phase 3	40
Enoxaparin	Sanofi	Pre-clinical	26
Clexane	Sanofi	Approved	35
Idrabiotaparinux sodium + Idraparinux sodium + Avidin + Placebo (for Avidin)	Sanofi	Phase 3	40
SanOrg34006 + LMW heparin + Unfractionated heparin + Vitamin K antagonist (VKA)	Sanofi	Phase 3	40
Rivaroxaban (Xarelto, BAY59-7939) + Standard of care	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto, BAY59-7939) + Rivaroxaban (Xarelto, BAY59-7939) + Unfractionated heparin + Warfarin	Bayer	Phase 3	37
Rivaroxaban (Xarelto, BAY59-7939) + Recommended VTE pharmacological treatments according to international guidelines	Bayer	Pre-clinical	23
Triptorelin Acetate 3.75mg intramuscular injection	Ipsen	Pre-clinical	23